» Articles » PMID: 12665253

Dose-dependent Protection of Cardiac Function by Propofol During Ischemia and Early Reperfusion in Rats: Effects on 15-F2t-isoprostane Formation

Overview
Specialties Pharmacology
Physiology
Date 2003 Apr 1
PMID 12665253
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

We examined the effects of propofol (2,6-diisopropylphenol) on functional recovery and 15-F2t-isoprostane generation during ischemia-reperfusion in Langendorff-perfused rat hearts. Before the induction of 40 min of global ischemia, hearts were perfused (10 min) with propofol at 5 (lo-P) or 12 microg/mL (hi-P) in saline or with saline only (control). During ischemia, saline, lo-P, or hi-P was perfused through the aorta at 60 microL/min. During the first 15 min of reperfusion, propofol (5 or 12 microg/mL) was continued, followed by perfusion with 5 microg/mL propofol for 75 min in both propofol-treated groups. After 90 min of reperfusion (Rep-90), heart tissues were harvested for assessment of antioxidant status. In hi-P, we observed increased latency to and greater reduction of ischemic contracture relative to the lo-P or control groups. 15-F2t-Isoprostane concentrations increased during ischemia and were significantly lower in hi-P and lo-P than in control (P < 0.01). At Rep-90, myocardial functional recovery was greater in both propofol-treated groups relative to control, and it correlated positively with tissue antioxidant capacity preservation. Tissue antioxidant capacity was better preserved in hi-P than in lo-P treatment (P < 0.05). We conclude that oxidant injury occurs during ischemia and reperfusion, and propofol provides dose-dependent protection primarily by enhancing tissue antioxidant capacity and reducing lipid peroxidation.

Citing Articles

Ferroptosis and its Potential Determinant Role in Myocardial Susceptibility to Ischemia/Reperfusion Injury in Diabetes.

Zhou D, Yang Y, Han R, He J, Liu D, Xia W Rev Cardiovasc Med. 2024; 25(10):360.

PMID: 39484139 PMC: 11522832. DOI: 10.31083/j.rcm2510360.


Salvianolic acids and its potential for cardio-protection against myocardial ischemic reperfusion injury in diabetes.

Jiang Y, Cai Y, Han R, Xu Y, Xia Z, Xia W Front Endocrinol (Lausanne). 2024; 14:1322474.

PMID: 38283744 PMC: 10811029. DOI: 10.3389/fendo.2023.1322474.


Propofol inhibits myocardial injury induced by microvesicles derived from hypoxia-reoxygenated endothelial cells via lncCCT4-2/CCT4 signaling.

Zhang X, Wang C, Xu H, Cai S, Liu K, Li S Biol Res. 2023; 56(1):20.

PMID: 37143143 PMC: 10161458. DOI: 10.1186/s40659-023-00428-3.


Efficacy of propofol-supplemented cardioplegia on biomarkers of organ injury in patients having cardiac surgery using cardiopulmonary bypass: A protocol for a randomised controlled study (ProMPT2).

Heys R, Angelini G, Joyce K, Smartt H, Culliford L, Maishman R Perfusion. 2023; 39(4):722-732.

PMID: 36794486 PMC: 7617284. DOI: 10.1177/02676591231157269.


Propofol inhibits oxidative stress injury through the glycogen synthase kinase 3 beta/nuclear factor erythroid 2-related factor 2/heme oxygenase-1 signaling pathway.

Zhang Z, Yan B, Li Y, Yang S, Li J Bioengineered. 2022; 13(1):1612-1625.

PMID: 35030972 PMC: 8805835. DOI: 10.1080/21655979.2021.2021062.